Skip to content

Advances in Motion

New Research and Treatment Options for IDH1 Mutant Tumors

Video

In This Video

  • Bob Carter, MD, PhD, is the director of Neurosurgical Oncology and co-director of the Brain Tumor Program
  • Here he discusses research in his department by Daniel Cahill, MD, PhD, who is leading research on IDH1 mutant brain tumors
  • Dr. Cahill is using intraoperative MRI and the very best in surgical therapy to maximize a patient's neurological function and avoiding morbidity

Bob Carter, MD, PhD, is the director of Neurosurgery and co-director of the Brain Tumor Program. In this video, he discusses research in his department by Neurosurgeon Daniel Cahill, MD, PhD, who is leading research on IDH1 mutant brain tumors. Dr. Cahill is using intraoperative MRI and the very best in surgical therapy to maximize a patient's neurological function and avoiding morbidity.

Transcript

One of my great pleasures as being the director of Neurosurgical Oncology and co-director of the Brain Tumor Program here, is to have an incredible team of physicians who are working to help patients with brain tumors.

One that I'd like to highlight is Dr. Dan Cahill, who's really leading our effort on IDH1 mutant tumors. These tumors affect a very young population, often patients in their 20s or 30s--in the prime of life. And often these patients have a residual disease; an incomplete resection has been performed because of the location of the tumor.

We feel we can make a substantial impact on their long-term prognosis and their quality of life by using the latest techniques.

Dr. Cahill has led our effort and has performed over 1,000 surgeries in our intraoperative brain MRI suite, trying to treat patients to give them, with the intraoperative MRI, the very best in surgical therapy, and at the same time maximize their neurological function and avoiding morbidity.

By leading this effort at our center, Dr. Cahill has brought a unique set of resources to be made available to patients with these types of low-grade tumors. By using some of the techniques that I've mentioned, and also bringing to bear his research, we think that we can offer for these patients the latest in clinical trials and other forms of therapy that will benefit them in the long-term.

Learn more about the Stephen E. and Catherine Pappas Center for Neuro-Oncology

Refer a patient to Mass General Neurosurgery

Related topics

Related

Mass General has developed a genotype-targeted therapy for glioma, designed to be given at the tumor site during surgery, and an accompanying rapid diagnostic.

Brain Tumor, Neuro-Oncology, Neuroscience, Neurosurgery, Oncology

Article

Related

Massachusetts General Hospital neurooncologists have identified a subgroup of IDH wild-type glioblastomas that have a distinct clinical and molecular profile. The findings may have significant implications for targeted therapy in these patients.

Brain Tumor, Neuroscience, Neurosurgery

Journal